Vnitr Lek 2021, 67(8):459-464 | DOI: 10.36290/vnl.2021.120

Optimal potassium levels in patients with heart failure

Radek Pudil
1 . interní kardioangiologická klinika LF UK a FN Hradec Králové

Heart failure therapy involves the use of a number drugs that significantly affect potassium levels. While diuretics decrease potassium levels, others (angiotensin converting enzyme inhibitors, AT2 receptor blockers, sacubitril/valsartan, spironolactone) increase. Patients also have several comorbidities that can significantly reduce renal function and thus affect the resulting potassium level. Decreased or elevated potassium levels can be very dangerous for the patient and therefore need to be monitored. In recent years, the results of several studies have been published that have focused on potassium levels and mortality and have shown that the optimal potassium levels in patients with heart failure should be between 4-5 mmol/L.

Keywords: heart failure, mortality, optimal level of kalemia, potassium.

Published: December 9, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pudil R. Optimal potassium levels in patients with heart failure. Vnitr Lek. 2021;67(8):459-464. doi: 10.36290/vnl.2021.120.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo‑Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A, Group ESCSD. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. Go to original source... Go to PubMed...
    2. Siegfierd R. The Discovery of Potassium and Sodium, and the Problem of the Chemical Elements. Isis. 1963;54:247-258. Go to original source... Go to PubMed...
    3. Miller HG. Potassium in animal nutrition, potassium in its relation to the growth of young rats. Jour Biol Chem. 1923;55:61-78. Go to original source...
    4. Follis RH O‑KE, McCollum EV. The Production of Cardiac and Renal Lesions in Rats by a Diet Extremely Deficient in Potassium. Am J Pathol. 1942;18(1):29-39.
    5. Skou JC. The influence of some cations on an adenosine triphosphatase from peripheral nerves. Biochim Biophys Acta. 1957;23(2):394-401. Go to original source... Go to PubMed...
    6. Rysava R. Hypokalémie. Interní Med. 2006;9:385-388.
    7. Skogestad J, Aronsen JM. Hypokalemia‑Induced Arrhythmias and Heart Failure: New Insights and Implications for Therapy. Front Physiol. 2018;9:1500. Go to original source... Go to PubMed...
    8. Bowling CB, Pitt B, Ahmed MI, Aban IB, Sanders PW, Mujib M, Campbell RC, Love TE, Aronow WS, Allman RM, Bakris GL, Ahmed A. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity‑matched studies. Circ Heart Fail. 2010;3(2):253-260. Go to original source... Go to PubMed...
    9. Aldahl M, Jensen AC, Davidsen L, Eriksen MA, Moller Hansen S, Nielsen BJ, Krogager ML, Kober L, Torp‑Pedersen C, Sogaard P. Associations of serum potassium levels with mortality in chronic heart failure patients. Eur Heart J. 2017;38(38):2890-2896. Go to original source... Go to PubMed...
    10. Leier CV, Dei Cas L, Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J. 1994;128(3):564-574. Go to original source... Go to PubMed...
    11. Osadchii OE. Mechanisms of hypokalemia‑induced ventricular arrhythmogenicity. Fundam Clin Pharmacol. 2010;24(5):547-559. Go to original source... Go to PubMed...
    12. Packer M. Potential role of potassium as a determinant of morbidity and mortality in patients with systemic hypertension and congestive heart failure. Am J Cardiol. 1990;65(10):45E-51E; discussion 52E. Go to original source... Go to PubMed...
    13. Sidhu K, Sanjanwala R, Zieroth S. Hyperkalemia in heart failure. Curr Opin Cardiol. 2020;35(2):150-155. Go to original source... Go to PubMed...
    14. Weir MR, Rolfe M. Potassium homeostasis and renin‑angiotensin‑aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010;5(3):531-548. Go to original source... Go to PubMed...
    15. Linde C, Qin L, Bakhai A, Furuland H, Evans M, Ayoubkhani D, Palaka E, Bennett H, McEwan P. Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK. ESC Heart Fail. 2019;6(2):280-290. Go to original source... Go to PubMed...
    16. Collins AJ, Pitt B, Reaven N, Funk S, McGaughey K, Wilson D, Bushinsky DA. Association of Serum Potassium with All‑Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes. Am J Nephrol. 2017;46(3):213-221. Go to original source... Go to PubMed...
    17. Nunez J, Bayes‑Genis A, Zannad F, Rossignol P, Nunez E, Bodi V, Minana G, Santas E, Chorro FJ, Mollar A, Carratala A, Navarro J, Gorriz JL, Lupon J, Husser O, Metra M, Sanchis J. Long‑Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality. Circulation. 2018;137(13):1320-1330. Go to original source... Go to PubMed...
    18. Hoss S, Elizur Y, Luria D, Keren A, Lotan C, Gotsman I. Serum Potassium Levels and Outcome in Patients With Chronic Heart Failure. Am J Cardiol. 2016;118(12):1868-1874. Go to original source... Go to PubMed...
    19. Matsushita K, Sang Y, Yang C, Ballew SH, Grams ME, Coresh J, Molnar MZ. Dyskalemia, its patterns, and prognosis among patients with incident heart failure: A nationwide study of US veterans. PLoS One. 2019; 14(8): e0219899. Go to original source... Go to PubMed...
    20. Desai AS, Liu J, Pfeffer MA, Claggett B, Fleg J, Lewis EF, McKinlay S, O'Meara E, Shah SJ, Sweitzer NK, Solomon S, Pitt B. Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. J Card Fail. 2018;24(5):313-320. Go to original source... Go to PubMed...
    21. Cooper LB, Hammill BG, Peterson ED, Pitt B, Maciejewski ML, Curtis LH, Hernandez AF. Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure. JAMA. 2015;314(18):1973-1975. Go to original source... Go to PubMed...
    22. Ferreira JP, Butler J, Rossignol P, Pitt B, Anker SD, Kosiborod M, Lund LH, Bakris GL, Weir MR, Zannad F. Abnormalities of Potassium in Heart Failure: JACC State‑of‑the‑Art Review. J Am Coll Cardiol. 2020;75(22):2836-2850. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.